OpenURL Connection Search

Select item for more details and to access through your institution.

Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.
Published in:
European Journal of Haematology, 2003, v. 70, n. 6, p. 398, doi. 10.1034/j.1600-0609.2003.00075.x
By:
- Miskin, H.;
- Yaniv, I.;
- Berant, M.;
- Hershko, C.;
- Tamary, H.
Publication type:
Article
First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 579, doi. 10.1002/hon.3164_434
By:
- Hawkes, E. A.;
- Lewis, K. L.;
- Doo, N. Wong;
- Patil, S. S.;
- Miskin, H. P.;
- Sportelli, P.;
- Kolibaba, K. S.;
- Normant, E.;
- Turpuseema, T.;
- Cheah, C. Y.
Publication type:
Article
Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax.
Published in:
Hematological Oncology, 2023, v. 41, p. 484, doi. 10.1002/hon.3164_356
By:
- Wallace, D. S.;
- Rowland, C.;
- Hill, B. T.;
- Baran, A. M.;
- Casulo, C.;
- Reagan, P. M.;
- Winter, A.;
- Karmali, R.;
- Winter, J. N.;
- Gordon, L. I.;
- Bui, A.;
- Sportelli, P.;
- Weiss, M. S.;
- Miskin, H. P.;
- Friedberg, J. W.;
- Ma, S.;
- Barr, P. M.
Publication type:
Article
ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.153_2880
By:
- Ribeiro, M. L;
- Reyes‐Garau, D;
- Vinyoles, M;
- Profitos‐Peleja, N;
- Santos, J. C;
- Armengol, M;
- Fernandez‐Serrano, M;
- Bech‐Serra, J. J;
- Blecua, P;
- Musulen, E;
- De la Torre, C;
- Miskin, H;
- Esteller, M;
- Bosch, F;
- Menendez, P;
- Normant, E;
- Roue, G
Publication type:
Article
TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.148_2880
By:
- Cheah, C. Y;
- Jurczak, W;
- Lasica, M;
- Wickham, N;
- Wróbel, T;
- Walewski, J;
- Yannakou, C. K;
- Cheung, S;
- Lewis, K. L;
- Długosz‐Danecka, M;
- Giannopoulos, K;
- Miskin, H. P;
- Tang, J.‐P;
- Normant, E;
- O'Connor, O. A;
- Ricart, A. D;
- Tam, C. S
Publication type:
Article
UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL.
Published in:
Hematological Oncology, 2017, v. 35, p. 54, doi. 10.1002/hon.2437_39
By:
- Davids, M.S.;
- Kim, H.T.;
- Nicotra, A.;
- Savell, A.;
- Francoeur, K.;
- Hellman, J.M.;
- Miskin, H.;
- Sportelli, P.;
- Bashey, A.;
- Stampleman, L.;
- Rueter, J.;
- Boruchov, A.;
- Arnason, J.E.;
- Jacobson, C.A.;
- Jacobsen, E.J.;
- Fisher, D.C.;
- Brown, J.R.
Publication type:
Article

Found: 6

Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation.

First‐in‐Human (FIH) Study of the Fully‐Human Kappa‐Lambda CD19/CD47 Bispecific Antibody TG‐1801 in Patients with B‐Cell Lymphoma.

Venetoclax based combination therapy does not overcome poor outcomes in BTKi‐refractory mantle cell lymphoma: phase 2 trial of umbralisib, ublituximab, and venetoclax.

ANTITUMORAL ACTIVITY OF THE NOVEL BTK INHIBITOR TG‐1701 IS ASSOCIATED WITH DISRUPTION OF IKAROS SIGNALING AND IMPROVEMENT OF ANTI‐CD20 THERAPY IN B‐CELL NON‐HODGKIN LYMPHOMA.

TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES.

UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL.